Teen Asthma Investigational Medication

Trial Objective

The purpose of this study is to determine if an investigational medication, QAW039, improves lung function in teens with uncontrolled asthma, compared to a placebo, a pill that does not contain the study medication.

Teen Asthma Investigational Medication

The study also will determine if QAW039 has side effects, how serious they are, and how many times they happen compared to the placebo. QAW039 is a medication taken by mouth that works by blocking a receptor —a protein molecule that receives chemical signals from outside the cell— called DP2. When DP2 is blocked, blood cells that cause inflammation, such as eosinophils —a type of disease-fighting white blood cell— cannot move into the lungs and cause narrowed airways and asthma symptoms like wheezing and shortness of breath. 

The Food and Drug Administration has not approved QAW039 for treatment of asthma. The investigational medication is not available for purchase or by prescription in the United States.


This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1030 or complete the form below.

Who Can Participate

Teens age 12-17 with a diagnosis of asthma for at least six months who have been treated with one of the following may be eligible to participate: (1) medium-dose inhaled corticosteroid (ICS) such as Flovent®, (2) high-dose ICS such as Xolair®, (3) low-dose ICS plus a long-acting beta agonist (LABA) such as Symbicort®, (4) low-dose ICS plus leukotriene receptor antagonist (LTRA) such as Singulair® or (4) medium-dose ICS plus LABA such as Advair®.

Estimated Time Commitment

About 9 visits over approximately 19 weeks

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Novartis Pharmaceuticals Corporation




Any Gender

Principal Investigators

Request More Information